LivaNova (LIVN) PT Raised to $97.00 at Needham & Company LLC
LivaNova (NASDAQ:LIVN) had its price objective upped by stock analysts at Needham & Company LLC from $93.00 to $97.00 in a research report issued to clients and investors on Tuesday, Marketbeat reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 17.23% from the stock’s current price.
LIVN has been the subject of a number of other research reports. Berenberg Bank reaffirmed a “buy” rating and issued a $70.00 price target on shares of LivaNova in a research note on Friday, August 11th. Canaccord Genuity reaffirmed a “hold” rating and issued a $71.00 price target on shares of LivaNova in a research note on Wednesday, September 20th. Jefferies Group raised their price target on LivaNova from $76.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, September 15th. Zacks Investment Research raised LivaNova from a “hold” rating to a “buy” rating and set a $89.00 price target for the company in a research note on Thursday, November 9th. Finally, BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research note on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $79.71.
LivaNova (NASDAQ:LIVN) opened at $82.74 on Tuesday. The company has a quick ratio of 1.42, a current ratio of 2.03 and a debt-to-equity ratio of 0.04. LivaNova has a fifty-two week low of $44.58 and a fifty-two week high of $88.56. The stock has a market cap of $4,242.62, a P/E ratio of 25.36, a PEG ratio of 2.64 and a beta of 0.61.
In other LivaNova news, Director Hugh M. Morrison sold 1,830 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total transaction of $161,040.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alfred J. Novak sold 2,000 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $85.77, for a total value of $171,540.00. The disclosure for this sale can be found here. Insiders sold 6,830 shares of company stock valued at $557,100 in the last ninety days. 0.28% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in LIVN. Vanguard Group Inc. lifted its position in LivaNova by 4.5% during the first quarter. Vanguard Group Inc. now owns 777,356 shares of the company’s stock valued at $38,098,000 after buying an additional 33,645 shares during the period. Bank of Montreal Can lifted its position in LivaNova by 18,000.8% during the second quarter. Bank of Montreal Can now owns 42,899 shares of the company’s stock valued at $2,625,000 after buying an additional 42,662 shares during the period. Russell Investments Group Ltd. purchased a new position in LivaNova during the second quarter valued at $957,000. Strs Ohio purchased a new position in LivaNova during the second quarter valued at $673,000. Finally, Bessemer Group Inc. purchased a new position in LivaNova during the second quarter valued at $220,000. 86.07% of the stock is owned by institutional investors and hedge funds.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.